Market Overview:
The global atenolol tablets market is expected to grow at a CAGR of 3.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of hypertension, angina, and arrhythmias across the globe. Additionally, rising awareness about the benefits of atenolol tablets is also contributing to the growth of this market. Based on type, the global atenolol tablets market can be segmented into 25mg, 50mg, and 100mg segments. The 25mg segment is expected to account for a major share of the global atenolol tablets market in 2018 owing to its lower dosage as compared with other dosages available in this category. However, with increasing awareness about health and growing demand for high-dose medications among consumers worldwide,the 100mg segment is projectedto registerthe highest CAGR duringthe forecast period from2018to2030. .However,.
Product Definition:
Atenolol is a beta blocker that is used to treat hypertension, angina, and heart failure. It works by blocking the effects of epinephrine and norepinephrine on the heart, which decreases the heart rate and blood pressure.
25mg:
25mg Atenolol is used for the treatment of hypertension and to lower the high blood pressure. It works by relaxing muscles in the arteries and veins, allowing more blood flow through them.
It is also used as an anti-clotting agent during cardiopulmonary bypass surgery or heart attack patients who are treated with angioplasty (a procedure to unblock an artery).
50mg:
Atenolol is used to treat high blood pressure and angina (chest pain) by blocking the constriction of blood vessels. It is also used as an anti-clotting agent in the treatment of atrial fibrillation, a type of heart arrhythmia. Atenolol tablets are available with different dosages to treat specific conditions. The dosage prescribed depends on several factors such as age, body weight, medical history and other medications taken along with it.
Application Insights:
The hypertension segment held the largest share of over 50.0% in 2017. Hypertension was the most common disorder treated with atenolol across the globe, followed by angina and arrhythmias. The high prevalence of hypertension coupled with its effective treatment through atenolol tablets is anticipated to fuel market growth during the forecast period.
Angina pectoris is expected to be one of the fastest growing segments owing to increasing incidence rates and awareness regarding early diagnosis & treatment among patients suffering from angina pectoris, which in turn will boost industry growth during the forecast period. Moreover, favorable reimbursement policies towards treatments such as lifestyle modification and medication for angina are further anticipated to propel demand for atenolol tablets over coming years.
Regional Analysis:
North America dominated the global atenolol tablets market in 2017. High adoption of cost-saving medication, increasing geriatric population and favorable reimbursement policies are some of the major factors contributing to its largest share. The U.S., which is one of the most developed nations in this region, accounted for a large share owing to high demand for advanced therapeutics and better healthcare facilities compared to developing nations.
Asia Pacific is expected to be one of the fastest growing regions during the forecast period due to rising disposable income leading towards improved healthcare access & infrastructure coupled with an increase in awareness regarding atenolol tablets usage among patients & physicians as well as manufacturers/suppliers (pharmaceuticals). Moreover, economic development along with improving lifestyle habits such as a reduction in salt intake may contribute towards increased cardiovascular diseases (CVD) risk factor prevalence thereby driving growth over coming years.
Growth Factors:
- Increasing prevalence of hypertension and other heart diseases: The global prevalence of hypertension is estimated to be around 1.13 billion in 2015 and is projected to reach 1.56 billion by 2025. This will create a large pool of patients who will require treatment, thereby driving the demand for atenolol tablets market.
- Rising geriatric population: The global geriatric population (aged 65 years or above) is expected to grow from 524 million in 2010 to nearly 1.5 billion by 2050, creating a large pool of patients with cardiovascular diseases that will need treatment, thereby propelling the growth of atenolol tablets market over the forecast period
Scope Of The Report
Report Attributes
Report Details
Report Title
Atenolol Tablets Market Research Report
By Type
25mg, 50mg, 100mg
By Application
Hypertension, Angina, Arrhythmias
By Companies
AstraZeneca, ACETO, Aurobindo Pharma, Sandoz, Mylan, Sun Pharmaceutical, Teva, Zydus Pharmaceuticals, Unique Pharmaceuticals, Ipca Laboratories, AstraZeneca
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
202
Number of Tables & Figures
142
Customization Available
Yes, the report can be customized as per your need.
Global Atenolol Tablets Market Report Segments:
The global Atenolol Tablets market is segmented on the basis of:
Types
25mg, 50mg, 100mg
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hypertension, Angina, Arrhythmias
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AstraZeneca
- ACETO
- Aurobindo Pharma
- Sandoz
- Mylan
- Sun Pharmaceutical
- Teva
- Zydus Pharmaceuticals
- Unique Pharmaceuticals
- Ipca Laboratories
- AstraZeneca
Highlights of The Atenolol Tablets Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 25mg
- 50mg
- 100mg
- By Application:
- Hypertension
- Angina
- Arrhythmias
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Atenolol Tablets Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Atenolol Tablets are a medication used to treat hypertension. They work by relaxing the blood vessels and reducing blood pressure.
Some of the key players operating in the atenolol tablets market are AstraZeneca, ACETO, Aurobindo Pharma, Sandoz, Mylan, Sun Pharmaceutical, Teva, Zydus Pharmaceuticals, Unique Pharmaceuticals, Ipca Laboratories, AstraZeneca.
The atenolol tablets market is expected to grow at a compound annual growth rate of 3.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Atenolol Tablets Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Atenolol Tablets Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Atenolol Tablets Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Atenolol Tablets Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Atenolol Tablets Market Size & Forecast, 2020-2028
4.5.1 Atenolol Tablets Market Size and Y-o-Y Growth
4.5.2 Atenolol Tablets Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 25mg
5.2.2 50mg
5.2.3 100mg
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hypertension
6.2.2 Angina
6.2.3 Arrhythmias
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Atenolol Tablets Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Atenolol Tablets Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 25mg
9.6.2 50mg
9.6.3 100mg
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hypertension
9.10.2 Angina
9.10.3 Arrhythmias
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 25mg
10.6.2 50mg
10.6.3 100mg
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hypertension
10.10.2 Angina
10.10.3 Arrhythmias
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 25mg
11.6.2 50mg
11.6.3 100mg
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hypertension
11.10.2 Angina
11.10.3 Arrhythmias
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 25mg
12.6.2 50mg
12.6.3 100mg
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hypertension
12.10.2 Angina
12.10.3 Arrhythmias
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 25mg
13.6.2 50mg
13.6.3 100mg
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hypertension
13.10.2 Angina
13.10.3 Arrhythmias
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Atenolol Tablets Market: Competitive Dashboard
14.2 Global Atenolol Tablets Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AstraZeneca
14.3.2 ACETO
14.3.3 Aurobindo Pharma
14.3.4 Sandoz
14.3.5 Mylan
14.3.6 Sun Pharmaceutical
14.3.7 Teva
14.3.8 Zydus Pharmaceuticals
14.3.9 Unique Pharmaceuticals
14.3.10 Ipca Laboratories
14.3.11 AstraZeneca
